Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial

The Lancet Diabetes and Endocrinology

Volumn 6, Issue 3, 2018, Pages 173-185

  Isidori, Andrea M ^a   Venneri, Mary Anna ^a   Graziadio, Chiara ^a   Simeoli, Chiara ^c   Fiore, Daniela ^a   Hasenmajer, Valeria ^a   Sbardella, Emilia ^a   Gianfrilli, Daniele ^a   Pozza, Carlotta ^a   Pasqualetti, Patrizio ^d   Morrone, Stefania ^a   Santoni, Angela ^b   Naro, Fabio ^a   Colao, Annamaria ^c   Pivonello, Rosario ^c   Lenzi, Andrea ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Service of Medical Statistics and Information Technology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HYDROCORTISONE; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADULT; ARTHRITIS; ARTICLE; BLOOD BIOCHEMISTRY; BODY MASS; BODY WEIGHT CHANGE; BODY WEIGHT LOSS; BREAST CYST; CIRCADIAN RHYTHM; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FAINTNESS; FATIGUE; FEMALE; GLUCOSE METABOLISM; HORMONE SUBSTITUTION; HUMAN; IMMUNOCOMPETENT CELL; INFECTION SENSITIVITY; INNATE IMMUNITY; ITALY; KIDNEY FAILURE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NAUSEA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; SINGLE BLIND PROCEDURE; SINUSITIS; SORE THROAT; THYROID PAPILLARY CARCINOMA; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT OBSTRUCTION; VERTIGO; ADOLESCENT; AGED; BODY WEIGHT; CLINICAL TRIAL; DRUG ADMINISTRATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADRENAL INSUFFICIENCY; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; BODY WEIGHT; CIRCADIAN RHYTHM; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; IMMUNITY, INNATE; MALE; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 85037661520     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30398-4     Document Type: Article

References (41)

1. Charmandari, E, Nicolaides, NC, Chrousos, GP, Adrenal insufficiency. Lancet 383 (2014), 2152–2167.
2. Hahner, S, Spinnler, C, Fassnacht, M, et al. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J Clin Endocrinol Metab 100 (2015), 407–416.
3. Bornstein, SR, Allolio, B, Arlt, W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 101 (2016), 364–389.
4. Castinetti, F, Sahnoun, M, Albarel, F, et al. An observational study on adrenal insufficiency in a French tertiary centre: real life versus theory. Ann Endocrinol 76 (2015), 1–8.
5. Rushworth, RL, Torpy, DJ, Modern hydrocortisone replacement regimens in adrenal insufficiency patients and the risk of adrenal crisis. Horm Metab Res 47 (2015), 637–642.
6. Bleicken, B, Hahner, S, Loeffler, M, et al. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin Endocrinol 72 (2010), 297–304.
7. Lovas, K, Gjesdal, CG, Christensen, M, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol 160 (2009), 993–1002.
8. Bleicken, B, Hahner, S, Loeffler, M, Ventz, M, Allolio, B, Quinkler, M, Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur J Endocrinol 159 (2008), 811–817.
9. Oster, H, Challet, E, Ott, V, et al. The functional and clinical significance of the 24-hour rhythm of circulating glucocorticoids. Endocr Rev 38 (2017), 3–45.
10. Debono, M, Ghobadi, C, Rostami-Hodjegan, A, et al. Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab 94 (2009), 1548–1554.
11. Johannsson, G, Bergthorsdottir, R, Nilsson, AG, Lennernas, H, Hedner, T, Skrtic, S, Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol 161 (2009), 119–130.
12. Johannsson, G, Nilsson, AG, Bergthorsdottir, R, et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 97 (2012), 473–481.
13. Giordano, R, Guaraldi, F, Marinazzo, E, et al. Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease. Endocrine 51 (2016), 360–368.
14. Quinkler, M, Miodini Nilsen, R, Zopf, K, Ventz, M, Oksnes, M, Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur J Endocrinol 172 (2015), 619–626.
15. Bancos, I, Hazeldine, J, Chortis, V, et al. Primary adrenal insufficiency is associated with impaired natural killer cell function: a potential link to increased mortality. Eur J Endocrinol 176 (2017), 471–480.
16. European Medicines Agency. Annex I. Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002185/WC500117637.pdf (accessed Oct 7, 2017).
17. Castell, S, Akmatov, MK, Obi, N, et al. Test-retest reliability of an infectious disease questionnaire and evaluation of self-assessed vulnerability to infections: findings of Pretest 2 of the German National Cohort. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 57 (2014), 1300–1307.
18. Sievers, C, Akmatov, MK, Kreienbrock, L, et al. Evaluation of a questionnaire to assess selected infectious diseases and their risk factors: findings of a multicenter study. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 57 (2014), 1283–1291.
19. Peter, HH, Goldacker, S, Haraldseide, J, et al. Construction and clinical validation of a questionnaire-based risk score to identify patients suffering from immunodeficiency or systemic autoimmunity. Br J Med Med Res 4 (2014), 4751–4769.
20. Oksnes, M, Bensing, S, Hulting, AL, et al. Quality of life in European patients with Addison's disease: validity of the disease-specific questionnaire AddiQoL. J Clin Endocrinol Metab 97 (2012), 568–576.
21. Plat, L, Leproult, R, L'Hermite-Baleriaux, M, et al. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab 84 (1999), 3082–3092.
22. Bergthorsdottir, R, Leonsson-Zachrisson, M, Oden, A, Johannsson, G, Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab 91 (2006), 4849–4853.
23. Bensing, S, Brandt, L, Tabaroj, F, et al. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol 69 (2008), 697–704.
24. Burman, P, Mattsson, AF, Johannsson, G, et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab 98 (2013), 1466–1475.
25. Rushworth, RL, Torpy, DJ, Adrenal insufficiency in Australia: is it possible that the use of lower dose, short-acting glucocorticoids has increased the risk of adrenal crises?. Horm Metab Res 47 (2015), 427–432.
26. Leelarathna, L, Breen, L, Powrie, JK, et al. Co-morbidities, management and clinical outcome of auto-immune Addison's disease. Endocrine 38 (2010), 113–117.
27. Smans, LC, Souverein, PC, Leufkens, HG, Hoepelman, AI, Zelissen, PM, Increased use of antimicrobial agents and hospital admission for infections in patients with primary adrenal insufficiency: a cohort study. Eur J Endocrinol 168 (2013), 609–614.
28. Lanier, LL, Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9 (2008), 495–502.
29. Gismondi, A, Cifaldi, L, Mazza, C, et al. Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood 104 (2004), 436–443.
30. Viel, S, Besson, L, Charrier, E, et al. Alteration of natural killer cell phenotype and function in obese individuals. Clin Immunol 177 (2016), 12–17.
31. Penack, O, Gentilini, C, Fischer, L, et al. CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia 19 (2005), 835–840.
32. Bergthorsdottir, R, Ragnarsson, O, Skrtic, S, et al. Visceral fat and novel biomarkers of cardiovascular disease in patients with Addison's disease; a case-control study. J Clin Endocrinol Metab, 2017 published online Sept 13. DOI:10.1210/jc.2017-01324.
33. Mamessier, E, Sylvain, A, Thibult, ML, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 121 (2011), 3609–3622.
34. Nilsson, AG, Marelli, C, Fitts, D, et al. Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency. Eur J Endocrinol 171 (2014), 369–377.
35. Scheiermann, C, Kunisaki, Y, Frenette, PS, Circadian control of the immune system. Nat Rev Immunol 13 (2013), 190–198.
36. Curtis, AM, Bellet, MM, Sassone-Corsi, P, O'Neill, LA, Circadian clock proteins and immunity. Immunity 40 (2014), 178–186.
37. Arjona, A, Sarkar, DK, Are circadian rhythms the code of hypothalamic-immune communication? Insights from natural killer cells. Neurochem Res 33 (2008), 708–718.
38. Frank, MG, Miguel, ZD, Watkins, LR, Maier, SF, Prior exposure to glucocorticoids sensitizes the neuroinflammatory and peripheral inflammatory responses to E coli lipopolysaccharide. Brain Behav Immun 24 (2010), 19–30.
39. Betterle, C, Scarpa, R, Garelli, S, et al. Addison's disease: a survey on 633 patients in Padova. Eur J Endocrinol 169 (2013), 773–784.
40. Hahner, S, Loeffler, M, Fassnacht, M, et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 92 (2007), 3912–3922.
41. Ekman, B, Bachrach-Lindstrom, M, Lindstrom, T, Wahlberg, J, Blomgren, J, Arnqvist, HJ, A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency. Clin Endocrinol 77 (2012), 18–25.